Showing 1 - 6 results of 6 for search 'Mark Laible', query time: 0.03s Refine Results
  1. 1
    Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue

    Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue by Kerstin Hartmann, Kornelia Schlombs, Mark Laible, Claudia Gürtler, Marcus Schmidt, Ugur Sahin, Hans-Anton Lehr

    Published 2018-10-01
    Get full text
    Article
  2. 2
    Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

    Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon... by Mark Laible, Kerstin Hartmann, Claudia Gürtler, Tobias Anzeneder, Ralph Wirtz, Stephan Weber, Thomas Keller, Ugur Sahin, Martin Rees, Annette Ramaswamy

    Published 2019-07-01
    Get full text
    Article
  3. 3
    Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR.

    Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. by Emanuele Caselli, Cristina Pelliccia, Valeria Teti, Guido Bellezza, Martina Mandarano, Ivana Ferri, Kerstin Hartmann, Mark Laible, Ugur Sahin, Zsuzsanna Varga, Chiara Lupi, Fabrizio Stracci, Angelo Sidoni

    Published 2021-01-01
    Get full text
    Article
  4. 4
    The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis

    The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis by Adrian Georg Simon, Su Ir Lyu, Mark Laible, Stefan Wöll, Özlem Türeci, Uğur Şahin, Hakan Alakus, Luca Fahrig, Thomas Zander, Reinhard Buettner, Christiane Josephine Bruns, Wolfgang Schroeder, Florian Gebauer, Alexander Quaas

    Published 2023-08-01
    Get full text
    Article
  5. 5
    Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study

    Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study by Francesco Schettini, Silvana Saracchini, Anna Bassini, Wally Marus, Serena Corsetti, Ilaria Specogna, Manuela Bertola, Elvia Micheli, Ralph M. Wirtz, Mark Laible, Uğur Şahin, Carla Strina, Manuela Milani, Sergio Aguggini, Richard Tancredi, Elena Fiorio, Sandro Sulfaro, Daniele Generali

    Published 2024-08-01
    Get full text
    Article
  6. 6
    An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®

    An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper® by Zsuzsanna Varga, Annette Lebeau, Hong Bu, Arndt Hartmann, Frederique Penault-Llorca, Elena Guerini-Rocco, Peter Schraml, Fraser Symmans, Robert Stoehr, Xiaodong Teng, Andreas Turzynski, Reinhard von Wasielewski, Claudia Gürtler, Mark Laible, Kornelia Schlombs, Heikki Joensuu, Thomas Keller, Peter Sinn, Ugur Sahin, John Bartlett, Giuseppe Viale

    Published 2017-05-01
    Get full text
    Article

Search Tools: